Microneedles for Melanoma Therapy: Exploring Opportunities and Challenges
Pharmaceutics · 28.04.2025 · 17 (5) · 579
DOI: 10.3390/pharmaceutics17050579 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 28.04.2025. Verfasst von Lufuno Nemakhavhani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laser Research Centre, University of Johannesburg, Johannesburg 2028, South Africa. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: South African Medical Research Council, South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation of South Africa, University of Johannesburg (URC).
Abstract (Originalsprache)
Melanoma is a type of skin cancer that originates in the melanocytes, the epidermis’ basal layer. The skin has traditionally been an attractive administration location for drug delivery in tumor therapy, and it is composed of three layers: the outermost stratum corneum (SC), the middle epidermis, and the deepest layer, the dermis. Melanoma can be treated using a variety of methods, such as chemotherapy, surgery, radiotherapy, and biological therapy, but all are expensive and have side effects. Furthermore, the SC is the primary barrier that contributes to the impermeability of the skin, which is a limitation in epidermal drug transport and can aid in achieving effective drug concentration with minimal side effects at the target location. Microneedles (MNs) are tiny needles that are easy to use, inexpensive, and non-toxic. In recent years, MNs have been significantly studied for the treatment of melanoma due to their excellent biocompatibility, minimal invasion, high patient compliance, simple penetration process, and high SC penetration rate. Most notably, MNs can provide efficient and seldom unpleasant delivery carriers and synergistic effectiveness by combining multi-model techniques with immunotherapy, gene therapy, photodynamic therapy (PDT), and photothermal treatment (PTT). This review will focus on biocompatibility, biodegradability, limitations, fabrication materials, release mechanisms, and delivery of the therapeutics of MNs for melanoma treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laser Research Centre, University of Johannesburg, Johannesburg 2028, South Africa.
ORCID-Profile: Heidi Abrahamse, Sathish Sundar Dhilip Kumar
Förderung
- South African Medical Research Council
- South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation of South Africa
- University of Johannesburg (URC)
- National Research Foundation (NRF)
- CSIR (Council for Scientific and Industrial Research)—NLC (National Laser Centre) Laser Rental Pool Programme
Zitieren
APA
Nemakhavhani, L., Abrahamse, H., & Dhilip Kumar, S. S. (2025). Microneedles for Melanoma Therapy: Exploring Opportunities and Challenges. Pharmaceutics, 17(5), 579. https://doi.org/10.3390/pharmaceutics17050579
Vancouver
Nemakhavhani L, Abrahamse H, Dhilip Kumar SS. Microneedles for Melanoma Therapy: Exploring Opportunities and Challenges. Pharmaceutics. 2025;17(5):579. doi:10.3390/pharmaceutics17050579
BibTeX
@article{Nemakhavhani2025,
author = {Nemakhavhani, Lufuno and Abrahamse, Heidi and Dhilip Kumar, Sathish Sundar},
title = {Microneedles for Melanoma Therapy: Exploring Opportunities and Challenges},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {5},
pages = {579},
doi = {10.3390/pharmaceutics17050579}
}
EUVIMED